Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ACTG1 Double Nickase Plasmid (h): sc-400006-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ACTG1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ACTG1 Double Nickase Plasmid (h) and ACTG1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ACTG1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: γ-Actin Antibody (1-17): sc-65638
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ACTG1 Double Nickase Plasmid (h) | sc-400006-NIC | 20 µg | $410.00 | |||
ACTG1 Double Nickase Plasmid (h2) | sc-400006-NIC-2 | 20 µg | $410.00 |
ACTG1 encodes cytoplasmic actin gamma 1, a core component of the actin cytoskeleton that supports cell shape, cortical tension, and force generation. ACTG1 participates in actin filament polymerization and remodeling that underlie processes such as cell migration, adhesion, cytokinesis, and mechanotransduction, integrating with Rho-family GTPase signaling and actin-binding protein networks. In human biology, perturbation of ACTG1-dependent cytoskeletal dynamics can alter intracellular trafficking and cellular architecture, making it relevant to studies of tissue development and stress responses. Genetic variation or dysregulation affecting ACTG1 has been associated with cytoskeleton-linked phenotypes, including forms of sensorineural hearing impairment and disorders involving altered cellular motility and structure.
ACTG1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ACTG1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ACTG1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ACTG1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ACTG1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.